The next generation: Fluoroquinolones in the management of acute lower respiratory infection in adults

Thorax

Volumn 55, Issue 1, 2000, Pages 83-85

  Moss, Peter J ^a   Finch, Roger G ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CEFACLOR; CEFTRIAXONE; CEFUROXIME; CEFUROXIME AXETIL; CIPROFLOXACIN; CLAVULANIC ACID; CLINAFLOXACIN; ERYTHROMYCIN; GATIFLOXACIN; GEMIFLOXACIN; GREPAFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ROXITHROMYCIN; SITAFLOXACIN; SPARFLOXACIN; THEOPHYLLINE; TROVAFLOXACIN; UNCLASSIFIED DRUG;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIOLOGY; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART ARRHYTHMIA; HUMAN; LOWER RESPIRATORY TRACT INFECTION; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; PHOTOSENSITIVITY; PRIORITY JOURNAL; QT INTERVAL; SHORT SURVEY; TORSADE DES POINTES; VERTIGO;

ADULT; ANTI-INFECTIVE AGENTS; FLUOROQUINOLONES; HUMANS; LUNG DISEASES; PNEUMONIA; RESPIRATORY TRACT DISEASES;

EID: 0034110445     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thorax.55.1.83     Document Type: Short Survey

References (49)

1. 1 American Thoracic Society. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity and initial antimicrobial therapy. Am Rev Respir Dis 1993;148:1418-26.
2. 2 Mandell LA, Niederman MS. Antimicrobial treatment of community acquired pneumonia in adults: a conference report. Can J Infect Dis 1993;4:25-8.
3. 3 British Thoracic Society. Guidelines for the management of community-acquired pneumonia in adults admitted to hospital. Br J Hosp Med 1993;49:346-50.
4. 4 Frieden TR, Mangi RJ. Inappropriate use of oral ciprofloxacin. JAMA 1990;264:1438-40.
5. 5 Lee BL, Kimbrough RC, Jones SR, et al. Infectious complications with respiratory pathogens despite ciprofloxacin therapy. N Engl J Med 1991;325:520-1.
6. 6 Korner RJ, Reeves DS, MacGowan AP. Dangers of oral fluoroquinolone treatment in community acquired upper respiratory tract infections. BMJ 1994;308:191-2.
7. 7 Fine MJ, Smith MA, Carson CA, et al. Prognosis and outcomes of patients with community-acquired pneumonia. JAMA 1996;275:134-41.
8. 8 Macfarlane JT. Treatment of lower respiratory tract infections. Lancet 1987;ii:1446-9.
9. 9 Sow O, Frechet M, Diallo AA, et al. Community-acquired pneumonia in adults: a study comparing clinical features and outcomes in Africa and Europe. Thorax 1996;51:385-8.
10. 10 Langtry HD, Lamb HM. Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract. Drugs 1998;56:487-515.
11. 11 Piddock LJ, Johnson M, Ricci V, et al. Activities of new fluoroquinolones against fluoroquinolone-resistant pathogens of the lower respiratory tract. Antimicrob Agents Chemother 1998;42:2956-60.
12. 12 Pankuch GA, Jacobs MR, Appelbaum PC. Antipneumococcal activity of grepafloxacin compared to that of other agents by time-kill methodology. Antimicrob Agents Chemother 1998;42:1263-5.
13. 13 Fuentes F, Marco F, Gimenez MJ, et al. Comparative in vitro activity of gemifloxacin against Strepotococcus pneumoniae clinical isolates exhibiting high ciprofloxacin MICs (abstract). 21st International Congress of Chemotherapy. 1999:P385.
14. 14 Milatovic D, Fluit A, Schmitz F-J, et al. In vitro activity of sitafloxin and six other fluoroquinolones. Part II: Gram-positive cocci (abstract). 21st International Congress of Chemotherapy. 1999:P601.
15. 15 Hoogkamp-Korstanje JA. In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections. J Antimicrob Chemother 1997;40:427-31.
16. 16 Hoogkamp-Korstanje JA, Dirks-Go SI, Kabel P, et al. Multicentre in-vitro evaluation of the susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis to ciprofloxacin, clarithromycin, co-amoxiclav and sparfloxacin. J Antimicrob Chemother 1997;39:411-4.
17. 17 Hammerschlag MR, Quemi KK, Roblin PM. In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae. Antimicrob Agents Chemother 1992;36:1573-4.
18. 18 Kaku M, Ishida K, Irifune K, et al. In vitro and in vivo activities of sparfloxacin against Mycoplasma pneumoniae. Antimicrob Agents Chemother 1994;38:738-41.
19. 19 Goldsmith CE, Moore JE, Murphy PG. Pneumococcal resistance in the UK. J Antimicrob Chemother 1997; 40(Suppl A):11-8.
20. 20 Thornsberry C, Ogilvie P, Kahn J, et al. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. Diagn Microbiol Infect Dis 1997;29:249-57.
21. 21 Pankuch GA, Jacobs MR, Appelbaum PC. Activity of CP 99,219 compared with DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, tosufloxacin, sparfloxacin and grepafloxacin against penicillin-susceptible and -resistant pneumococci. J Antimicrob Chemother 1995; 35:230-1.
22. 22 Vila J, Ruiz J, Sanchez F, et al. Increase in quinolone resistance in a Haemophilus influenzae strain isolated from a patient with recurrent respiratory infections treated with ofloxacin. Antimicrob Agents Chemother 1999;43:161-2.
23. 23 Pan XS, Fisher LM. Targetting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targetting of gyrase or topoisomerase Iv by quinolones. Antimicrob Agents Chemother 1997;45:471-4.
24. 24 Chen DK, McGeer A, De Azavedo JC, et al. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med 1999;341:233-9.
25. 25 Norrby SR. Grepafloxacin in respiratory tract infections: are we ready to accept a quinolone for empirical treatment? J Antimicrob Chemother 1997;40(Suppl A):99-101.
26. 26 Zeller V, Fourgeaud M, Moreau NJ. Accumulation of fluoroquinolones by Streptococcus pneumoniae and resistance arising from active fluoroquinolone efflux (abstract). 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1997:C57.
27. 27 Broskey J, Coleman K, Gwynn M, et al. Quinolone resistance mechanisms in 17 strains of Streptococcus pneumoniae and comparative sensitivity to gemifloxacin (abstract). 21st International Congress of Chemotherapy. 1999:P391.
28. 28 Wise R, Honeybourne D. Pharmacokinetics and pharmacodynamics of fluoroquinolones in the respiratory tract. Eur Respir J 1999;14:221-9.
29. 29 File TM, Segreti J, Dunbar L, et al. A multicenter, randomised study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother 1997;41:1965-72.
30. 30 Norrby SR, Petermann W, Willcox PA, et al. Levofloxacin versus ceftriaxone in the treatment of pneumonia in hospitalised patients. Antiinfective Drugs Chemother 1998;16:62.
31. 31 Carbon C. Comparative study of levofloxacin and co-amoxiclav in the treatment of community-acquired pneumonia in adults (abstract). 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1997:PLM70.
32. 32 Lode H, Garau J, Grassi C, et al. Treatment of community-acquired pneumonia: a randomised comparison of sparfloxacin, amoxycillin/clavulanic acid and erythromycin. Eur Respir J 1996;8:1999-2007.
33. 33 Ortqvist A, Valtonen M, Cars O, et al. A multi-centre, double-blind, randomised study comparing sparfloxacin with roxithromycin. Chest 1996;110:1499-506.
34. 34 Donowitz GR, Brandon ML, Salisbury JL, et al. Sparfloxacin versus cefaclor in the treatment of patients with community-acquired pneumonia: a randomised, double-masked, comparative, multi-center study. Clin Ther 1997; 19:936-53.
35. 35 Aubier M, Verster R, Regamey C, et al. Once-daily sparfloxacin versus high-dosage amoxycillin in the treatment of community-acquired, suspected pneumococcal pneumonia in adults. Clin Infect Dis 1998;26:1312-20.
36. 36 Portier H, May T, Proust A, et al. Comparative efficacy of sparfloxacin in comparison with amoxycilin plus ofloxacin in the treatment of community-acquired pneumonia. J Antimicrob Chemother 1996;37:83-91.
37. 37 Tremolieres F, de Kock F, Pluck N, et al. Trovafloxacin versus high-dose amoxicillin (1 g three times daily) in the treatment of community-acquired bacterial pneumonia. Eur J Clin Microbiol Infect Dis 1998;17:447-53.
38. 38 O'Doherty B, Dutchman DA, Pettit R, et al. Randomised, double-blind, comparative study of grepafloxacin and amoxycillin in the treatment of patients with community-acquired pneumonia. J Antimicrob Chemother 1997;40:73-81.
39. 39 DeAbate CA, Russel M, McElvaine P, et al. Multicenter randomised study comparing levofloxacin and cefuroxime axetil in the treatment of acute bacterial exacerbations of chronic bronchitis. Clin Infect Dis 1996;23:914.
40. 40 Allegra L, Konietzko N, Leophonte P, et al. Comparative safety and efficacy of sparfloxacin in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a double-blind, randomised, parallel, multicentre study. J Antimicrob Chemother 1996;37(Suppl A):93-104.
41. 41 Lode H, Zellweger J, Asmervik J. Short course grepafloxacin therapy for 5 days is as effective as 10 days therapy with co-amoxiclav in acute exacerbations of chronic bronchitis (abstract). 21st International Congress of Chemotherapy. 1999:P436.
42. 42 European Agency for the Evaluation of Medicinal Products. Public statement on Trovan/Trovan IV/Turvel/Turvel IV. 15 June 1999.
43. 43 Glaxo Wellcome. Raxar: summary of product characteristics 1997. Glaxo Wellcome, Greenford, UK.
44. 44 Rubinstein E. Safety profile of sparfloxacin in the treatment of respiratory tract infections. J Antimicrob Chemother 1996;37(Suppl A):145-60.
45. 45 Dupont H, Timsit JF, Souweine B, et al. Torsades de pointes probably related to sparfloxacin. Eur J Clin Microbiol Infect Dis 1996;15:350-1.
46. 46 Bartlett JG, Breiman RF, Mandell LA, et al. Community-acquired pneumonia in adults: guidelines for management. Clin Infect Dis 1998;26:811-38.
47. 47 Huchon G, Woodhead M, Gialdroni-Grassi G, et al. Guidelines for management of adult community-acquired lower respiratory infections. Eur Respir J 1998;11:986-91.
48. 48 Stein GE, Havlichek DH. Sparfloxacin: potential clinical and economic impact in the treatment of respiratory infections. Pharmacotherapy 1997;17:1139-47.
49. 49 British Thoracic Society. British Thoracic Society guidelines for the management of chronic obstructive pulmonary disease. Thorax 1997;52(Suppl 5):S1-28.